AOD-9604 vs Tesamorelin
An hGH fragment selected to exclude growth signaling, against a GHRH analog that deliberately drives the full axis.
Metabolic
AOD-9604
C-terminal fragment of human growth hormone studied for lipolytic activity without the growth-promoting effects of the full hormone.
Growth Hormone
Tesamorelin
Stabilized 44-amino-acid GHRH analog — the longest GHRH sequence in common research use.
Side by side
| Dimension | AOD-9604 | Tesamorelin |
|---|---|---|
| Molecular weight A 2.8× difference in mass — these are not comparable on a milligram-for-milligram basis. | 1815.08 g/mol | 5135.86 g/mol |
| Size class | mid-length peptide | long peptide |
| CAS number | 221231-10-3 | 218949-48-5 |
| Research area | metabolic | growth hormone |
| Sequence | Not published as a linear sequence | Not published as a linear sequence |
| Available sizes | 5mg | 10mg, 15mg |
| Entry price | $44 | $64 |
| Cost per mg | $8.80 | $5.93 |
Mechanism
AOD-9604
AOD-9604 corresponds to residues 176-191 of human growth hormone, the C-terminal region associated in early work with the hormone's effects on adipose tissue. The research premise is separation of function: retaining lipolytic activity while excluding the IGF-1-mediated growth signaling of full-length hGH. Published human trial results have been considerably more modest than the preclinical rodent data suggested — a gap worth knowing before designing around it.
Tesamorelin
Tesamorelin is a synthetic analog of full-length human GHRH(1-44) with a trans-3-hexenoyl group attached at the N-terminus, conferring resistance to DPP-4 cleavage. It is distinguished from sermorelin and Modified GRF (1-29) by sequence length: those are truncated to the first 29 residues, whereas tesamorelin retains the complete 44-residue sequence. It has an established clinical literature, which is uncommon in this catalog.
Research applications
AOD-9604
- Lipolysis and β-adrenergic pathway assays in adipocyte culture
- Comparative studies against full-length hGH
- IGF-1 independence verification studies
Tesamorelin
- GHRH receptor binding and activation studies
- Comparative studies against truncated GHRH analogs
- Visceral adipose tissue metabolism research
- IGF-1 axis response profiling
Common questions
What is the difference between AOD-9604 and Tesamorelin?
AOD-9604 is c-terminal fragment of human growth hormone studied for lipolytic activity without the growth-promoting effects of the full hormone. Tesamorelin is stabilized 44-amino-acid GHRH analog — the longest GHRH sequence in common research use. They differ in molecular weight (1815.08 vs 5135.86 g/mol) and in the pathways they are studied against.
Which is more cost-effective per milligram, AOD-9604 or Tesamorelin?
Tesamorelin is lower at approximately $5.93 per milligram at its best tier, against $8.80 for the other. Cost per milligram is only meaningful relative to the concentrations a given protocol requires, since these compounds are not used at comparable masses.
Can AOD-9604 and Tesamorelin be studied together?
Combination designs appear in the published literature for a number of these compounds. Whether it is appropriate for a given protocol depends entirely on the model and endpoint. We supply research compounds and do not provide protocol guidance — consult the primary literature for your specific model.
How should AOD-9604 and Tesamorelin be stored?
Store lyophilized at -20°C protected from light. Reconstituted at 2-8°C for up to 30 days. For Tesamorelin: Store lyophilized at -20°C protected from light. Reconstituted at 2-8°C for up to 30 days.
All products are intended strictly for laboratory research use. Not for human or veterinary use. Not for diagnostic or therapeutic use. Not a drug, food, or cosmetic.
Comparison generated from NuVida Vital catalog data. Every specification is reconciled against the certificate of analysis for the shipped batch.